Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $129.43

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have been given a consensus rating of "Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $129.43.

A number of research firms have weighed in on LNTH. JMP Securities restated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective on the stock. Truist Financial upped their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 over the last 90 days. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the 4th quarter worth approximately $27,000. Summit Securities Group LLC bought a new position in Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. raised its stake in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC purchased a new position in Lantheus during the third quarter valued at $60,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Lantheus stock traded down $2.19 during midday trading on Friday, reaching $95.23. 139,214 shares of the stock were exchanged, compared to its average volume of 938,064. Lantheus has a 52 week low of $58.46 and a 52 week high of $126.89. The firm has a market cap of $6.52 billion, a PE ratio of 15.85 and a beta of 0.38. The company's fifty day moving average is $93.45 and its 200-day moving average is $96.29.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.